Waldenström Macroglobulinemia: Review of Pathogenesis and Management
- 7 March 2017
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (5), 252-262
- https://doi.org/10.1016/j.clml.2017.02.028
Abstract
No abstract availableFunding Information
- National Cancer Institute (P30 CA023074, T35 HL07479)
This publication has 67 references indexed in Scilit:
- Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse ModelsISRN Hematology, 2013
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 2011
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaLeukemia, 2010
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003Blood, 2009
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- Lymphoplasmacytic Lymphoma/Waldenstrom MacroglobulinemiaAdvances in Anatomic Pathology, 2005
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003